Stock Ratings / Health Care / JUNS / insiders

MBIO (43) CMND (48) DCOY (45) SXTP (50) ⌘ Pro Terminal →

Jupiter Neurosciences Inc. (JUNS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.37 -5.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Jupiter Neurosciences Inc. (JUNS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JUNS)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

JUNS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (JUNS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on JUNS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JUNS)

✓Walkthrough of JUNS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JUNS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.66%▲ RESISTANCE BREAKOUT

2026-10-30O $2.40H $2.41L $2.05C $2.37VOL 17.8K

RES: $0.72SUP: $1.80SMA50: $3.16SMA200: $20.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JUNS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JUNS Butterfly Map → + Track JUNS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JUNS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JUNS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JUNS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JUNS)

Health Care Rank #885 of 1016 ⚔️ MBIO vs JUNS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JUNS vs. MBIO, CMND, DCOY, SXTP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Jupiter Neurosciences Inc. (JUNS) ranks #885 by composite RQD confidence (33/100, grade E) and #978 by equity capitalization ($3.1M). Within this direct 5-issuer industry benchmark cohort, JUNS leads on earnings valuation at N/A trailing P/E, while JUNS leads on capital efficiency and profitability with -35.0% ROIC and 80.6% gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with JUNS at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JUNS ACTIVE Jupiter Neurosciences Inc.	E	33/100	—	80.6%	-35.0%	-5.20%	$3.1M	Benchmark Subject
MBIO Mustang Bio Inc.	D-	43/100	—	—	-35.0%	+9.00%	$3.0M	/mbio-vs-juns →
CMND Clearmind Medicine Inc.	D	48/100	—	—	—	-3.46%	$3.0M	/cmnd-vs-juns →
DCOY Decoy Therapeutics Inc.	D	45/100	—	—	-35.0%	+11.82%	$2.9M	/dcoy-vs-juns →
SXTP 60 Degrees Pharmaceuticals Inc.	D	50/100	—	22.3%	-35.0%	+11.87%	$3.3M	/sxtp-vs-juns →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001679628

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jupiter Neurosciences Inc. (JUNS) reported GAAP revenue of $21.8K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.6M, operating cash flow of -$5.4M, and free cash flow of -$5.4M (-38.4% YoY). On the balance sheet, JUNS closed FY2025 with $5.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$21.8K	-$8.6M	-$5.4M	-$5.4M	$5.6M	—
FY2024 (FY)	2024-12-31	$0	-$2.4M	-$3.9M	-$3.9M	$6.2M	—
FY2023 (FY)	2023-12-31	$0	-$4.8M	-$481.0K	-$481.0K	—	—

3. JUNS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JUNS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Jupiter Neurosciences Inc. (NASDAQ: JUNS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.37 (-5.20% 1D, market cap $3.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JUNS ranks #885 in composite RQD confidence.

How does JUNS compare to MBIO and CMND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JUNS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 80.6%, and ROIC of -35.0%. By comparison, MBIO (Mustang Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M) and CMND (Clearmind Medicine Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, JUNS leads on earnings multiple (N/A) while JUNS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JUNS?

Per JUNS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001679628), Jupiter Neurosciences Inc. generated $21.8K in revenue, -$8.6M in net income, and -$5.4M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JUNS trading relative to its 50-day, 200-day, and 52-week technical levels?

JUNS last traded at $2.37 (-5.20% on volume of 7,416 shares), positioning the stock -25.00% below its 50-day simple moving average ($3.16) and -88.47% below its 200-day simple moving average ($20.56). Across its 52-week range of $2.05 to $105.00, JUNS sits at the 0.3% percentile with a 14-day RSI of 32.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.07 to $2.67).

JUNS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are JUNS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies JUNS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: JUNS RQD Cockpit JUNS 12M Forecast JUNS Earnings & Move JUNS Dividends & DRIP JUNS Insiders & 13F JUNS Whale Options JUNS Profit Sankey JUNS News & Why